Skip to main contentSkip to navigation
Sirius Investors

AnaptysBio, Inc. (ANAB) Financial Metrics

This dashboard provides comprehensive financial metrics and analysis to help evaluate AnaptysBio, Inc.'s investment potential. View key valuation ratios, profitability metrics, growth indicators, and historical trends to make informed investment decisions.

Financial Metrics Score

Valuation Metrics

Sector benchmarks: Industrials

2025
P/E Ratio
-70.26
Earnings Deficit
P/B Ratio
24.14
Weak
WeakModerateStrong
Earnings Yield
-1.47%
Yield Gap

Profitability Health

2025
Return on Equity
-35.56%
Weak
WeakModerateStrong
Operating Margin
20.42%
Strong
WeakModerateStrong
Net Profit Margin
-5.64%
Weak
WeakModerateStrong

Growth Indicators

2025
Revenue Growth
157.01%
Strong
WeakModerateStrong
Net Income Growth
90.89%
Strong
WeakModerateStrong
EPS Growth
91.02%
Strong
WeakModerateStrong

Efficiency & Liquidity

2025
Current Ratio
9.07
Strong
WeakModerateStrong
Quick Ratio
9.07
Strong
WeakModerateStrong
Asset Turnover
0.64x
Moderate
WeakModerateStrong
Inventory Turnover
-
No data

Cash Flow & Resilience

Core fortress metrics for cash-rich balance sheets in high-inflation / tech-volatility regimes

2025
Free Cash Flow Yield
2.18%
Weak
WeakModerateStrong
EV / Free Cash Flow
34.37x
Moderate
WeakModerateStrong
Net Debt / EBITDA
-3.24x
Strong
WeakModerateStrong
Interest Burden (EBT / EBIT)
-0.273
Weak
WeakModerateStrong
Return on Invested Capital
14.61%
Weak
WeakModerateStrong
Cash Conversion Cycle
-530.46 days
Strong
WeakModerateStrong

Fortress screener guardrails

2/4 passing
  • FCF Yield > 3%
  • Net Debt / EBITDA < 1.5x
  • ROIC > 20%
  • Cash Conversion Cycle < 0 days

Financial Statements

Want to see the complete financial picture? View detailed financial statements including income statements, balance sheets, and cash flow statements for ANAB.

View Financial Statements